📊 CELG-RI Key Takeaways
Is Bristol Myers Squibb Co (CELG-RI) a Good Investment?
Bristol Myers Squibb demonstrates solid fundamental health with strong profitability margins (63.8% gross, 14.6% net) and exceptional cash generation (FCF of $12.8B, 26.7% margin). However, revenue stagnation (-0.2% YoY) and elevated leverage (2.43x debt-to-equity) warrant caution, despite manageable interest coverage of 21.9x and strong operational efficiency metrics.
Bristol Myers Squibb shows solid core fundamentals, with strong gross margins, healthy free cash flow generation, and ample interest coverage supporting financial stability. However, revenue and net income are essentially flat year over year, and the balance sheet remains heavily leveraged, which tempers the quality of growth and limits upside from fundamentals alone.
Why Buy Bristol Myers Squibb Co Stock? CELG-RI Key Strengths
- Exceptional free cash flow generation of $12.8B with 26.7% FCF margin indicating robust operational cash conversion
- Strong profitability with gross margin of 63.8% and net margin of 14.6%, reflecting pricing power and cost discipline
- Excellent interest coverage ratio of 21.9x demonstrates comfortable debt servicing capacity despite high absolute debt levels
- High return on equity of 38.2% indicates efficient capital deployment in shareholder value creation
- Strong profitability profile with 63.8% gross margin and 19.4% operating margin
- Robust cash generation with $12.85B in free cash flow and a 26.7% FCF margin
- Manageable near-term financial health with 1.26x current ratio and 21.9x interest coverage
CELG-RI Stock Risks: Bristol Myers Squibb Co Investment Risks
- Revenue stagnation with flat year-over-year growth (-0.2%) suggests mature portfolio without clear growth catalysts
- Elevated leverage with debt-to-equity ratio of 2.43x and $44.8B long-term debt; vulnerable to rising interest rates
- Modest current ratio of 1.26x indicates tightened short-term liquidity relative to current liabilities
- Pharmaceutical industry exposure to patent expirations, pricing pressures, and regulatory headwinds
- Revenue and net income are flat, indicating limited underlying growth momentum
- High leverage with $44.83B in long-term debt and 2.43x debt-to-equity
- ROE is strong but partly reflects a relatively small equity base, which can amplify balance sheet risk
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Debt reduction progress and leverage ratio improvement toward healthier 2.0x threshold
- Free cash flow sustainability and maintenance of 25%+ FCF margins
- Operating margin stability amid pricing and cost pressures in pharma sector
- Revenue growth and operating margin trend
- Free cash flow durability relative to debt reduction
Bristol Myers Squibb Co (CELG-RI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
CELG-RI Profit Margin, ROE & Profitability Analysis
CELG-RI vs Healthcare Sector: How Bristol Myers Squibb Co Compares
How Bristol Myers Squibb Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bristol Myers Squibb Co Stock Overvalued? CELG-RI Valuation Analysis 2026
Based on fundamental analysis, Bristol Myers Squibb Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bristol Myers Squibb Co Balance Sheet: CELG-RI Debt, Cash & Liquidity
CELG-RI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bristol Myers Squibb Co's revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $3.86 reflects profitable operations.
CELG-RI Revenue Growth, EPS Growth & YoY Performance
CELG-RI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.9B | $1.2B | $0.60 |
| Q2 2025 | $12.2B | $1.3B | $0.64 |
| Q1 2025 | $11.2B | $2.5B | $1.20 |
| Q3 2024 | $11.0B | $1.2B | $0.60 |
| Q2 2024 | $11.2B | $1.7B | $0.83 |
| Q1 2024 | $11.3B | $2.3B | $1.07 |
| Q3 2023 | $11.0B | $1.6B | $0.75 |
| Q2 2023 | $11.2B | $1.4B | $0.66 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bristol Myers Squibb Co Dividends, Buybacks & Capital Allocation
CELG-RI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bristol Myers Squibb Co (CIK: 0000014272)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775161840.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775161759.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775161696.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775161640.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775161564.xml | View → |
❓ Frequently Asked Questions about CELG-RI
What is the AI rating for CELG-RI?
Bristol Myers Squibb Co (CELG-RI) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELG-RI's key strengths?
Claude: Exceptional free cash flow generation of $12.8B with 26.7% FCF margin indicating robust operational cash conversion. Strong profitability with gross margin of 63.8% and net margin of 14.6%, reflecting pricing power and cost discipline. ChatGPT: Strong profitability profile with 63.8% gross margin and 19.4% operating margin. Robust cash generation with $12.85B in free cash flow and a 26.7% FCF margin.
What are the risks of investing in CELG-RI?
Claude: Revenue stagnation with flat year-over-year growth (-0.2%) suggests mature portfolio without clear growth catalysts. Elevated leverage with debt-to-equity ratio of 2.43x and $44.8B long-term debt; vulnerable to rising interest rates. ChatGPT: Revenue and net income are flat, indicating limited underlying growth momentum. High leverage with $44.83B in long-term debt and 2.43x debt-to-equity.
What is CELG-RI's revenue and growth?
Bristol Myers Squibb Co reported revenue of $48.2B.
Does CELG-RI pay dividends?
Bristol Myers Squibb Co pays dividends, with $5,045.0M distributed to shareholders in the trailing twelve months.
Where can I find CELG-RI SEC filings?
Official SEC filings for Bristol Myers Squibb Co (CIK: 0000014272) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELG-RI's EPS?
Bristol Myers Squibb Co has a diluted EPS of $3.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CELG-RI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bristol Myers Squibb Co has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CELG-RI stock overvalued or undervalued?
Valuation metrics for CELG-RI: ROE of 38.2% (sector avg: 15%), net margin of 14.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy CELG-RI stock in 2026?
Our dual AI analysis gives Bristol Myers Squibb Co a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CELG-RI's free cash flow?
Bristol Myers Squibb Co's operating cash flow is $14.2B, with capital expenditures of $1.3B. FCF margin is 26.7%.
How does CELG-RI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 14.6% (avg: 12%), ROE 38.2% (avg: 15%), current ratio 1.26 (avg: 2).
Is Bristol Myers Squibb Co carrying too much debt?
CELG-RI has a debt-to-equity ratio of 2.43x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.26 suggests adequate short-term liquidity.
Why is CELG-RI's return on equity (ROE) so high?
Bristol Myers Squibb Co has a return on equity of 38.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 14.6% net margin.